Skip to search formSkip to main contentSkip to account menu

Beclamide

Known as: N-benzyl-3-chloropropionamide 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

Posedrinechloracon

Broader (1)

Propionates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1995
1995
Metabolism of Beclamide after a Single Oral Dose in Man: Quantitative Studies
A simple reverse phase HPLC assay is described for the determination of the anticonvulsant compound, beclamide and its 3‐ and 4… 
1991
1991
Acute Effects of Beclamide on Brain Regional Monoamine Concentrations, their Metabolites and Radioligand Binding Studies
Abstract— The effects of beclamide on regional brain monoamine levels and radioligand binding have been studied in rats. One hour… 
1990
1990
Comparison of the inhibitory action of aminobeclamide and beclamide on socially offensive behaviour
Abstract— The inhibitory effects of aminobeclamide (N‐(p‐aminobenzyl)‐β‐chloropropionamide) on socially offensive behaviour has… 
1988
1988
Effects of beclamide on isolation‐induced aggression and locomotor activity in mice
Abstract— The anti‐aggressive effects of orally administered beclamide (N‐Benzyl‐β‐chloropropionamide) have been studied in male… 
1984
1984
[Simultaneous high performance liquid chromatographic determination of 8 anti-epileptics and sedatives in plasma. Use of a radial compression column system].
The authors describe a method of assaying anti-epileptic and sedative drugs by high performance liquid chromatography. This… 
1979
1979
Metabolism of beclamide, N-benzyl-3-chloropropionamide, in man.
1. Following oral administration of [14C]beclamide to human subjects there was almost complete elimination of radioactivity in… 
1977
1977
[Effects of beclamide on animal behavior].
1975
1975
Studies of plasma levels and the excretion of beclamide in normal human subjects [proceedings].
1970
1970
OBSERVATIONS ON THE USE OF BECLAMIDE (NYDRANE)IN A CHILD PSYCHIATRIC CLINIC
1967
1967
A TRIAL OF BECLAMIDE (NYDRANE) IN MENTALLY SUBNORMAL PATIENTS WITH DISORDERS OF BEHAVIOUR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)